Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane Huang

Showing results (101-110 of 126) with videos related to

Pageof 13
Sort By:
Leukemia & Lymphoma|February 17, 2023
Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosisWei Xu, Shenmiao Yang, Keshu Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2021
Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker AnalysisYuqin Song, Quanli Gao, Huilai Zhang, et al.
Blood|July 26, 2019
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLLConstantine S Tam, Judith Trotman, Stephen Opat, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2026
PD-1 blockade drug holiday improves exhausted progenitor CD8 T cell (Tpex) reinvigoration by avoiding Tpex adaptive resistanceShin Foong Ngiow, Ryan P O'Connell, Sasikanth Manne, et al.
Cell|August 9, 2024
LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicityShin Foong Ngiow, Sasikanth Manne, Yinghui Jane Huang, et al.
Immunity|May 13, 2020
Developmental Relationships of Four Exhausted CD8<sup>+</sup> T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control MechanismsJean-Christophe Beltra, Sasikanth Manne, Mohamed S Abdel-Hakeem, et al.
Cell|August 9, 2024
LAG-3 and PD-1 synergize on CD8<sup>+</sup> T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunityLawrence P Andrews, Samuel C Butler, Jian Cui, et al.
Nature Immunology|October 21, 2022
Shared and distinct biological circuits in effector, memory and exhausted CD8<sup>+</sup> T cells revealed by temporal single-cell transcriptomics and epigeneticsJosephine R Giles, Shin Foong Ngiow, Sasikanth Manne, et al.
Haematologica|October 15, 2020
Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletionConstantine S Tam, Tadeusz Robak, Paolo Ghia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2022
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III TrialPeter Hillmen, Barbara Eichhorst, Jennifer R Brown, et al.
Pageof 13

Showing results (101-110 of 126) with videos related to

Sort By:
Pageof 13
Leukemia & Lymphoma|February 17, 2023
Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosisWei Xu, Shenmiao Yang, Keshu Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2021
Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker AnalysisYuqin Song, Quanli Gao, Huilai Zhang, et al.
Blood|July 26, 2019
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLLConstantine S Tam, Judith Trotman, Stephen Opat, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2026
PD-1 blockade drug holiday improves exhausted progenitor CD8 T cell (Tpex) reinvigoration by avoiding Tpex adaptive resistanceShin Foong Ngiow, Ryan P O'Connell, Sasikanth Manne, et al.
Cell|August 9, 2024
LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicityShin Foong Ngiow, Sasikanth Manne, Yinghui Jane Huang, et al.
Immunity|May 13, 2020
Developmental Relationships of Four Exhausted CD8<sup>+</sup> T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control MechanismsJean-Christophe Beltra, Sasikanth Manne, Mohamed S Abdel-Hakeem, et al.
Cell|August 9, 2024
LAG-3 and PD-1 synergize on CD8<sup>+</sup> T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunityLawrence P Andrews, Samuel C Butler, Jian Cui, et al.
Nature Immunology|October 21, 2022
Shared and distinct biological circuits in effector, memory and exhausted CD8<sup>+</sup> T cells revealed by temporal single-cell transcriptomics and epigeneticsJosephine R Giles, Shin Foong Ngiow, Sasikanth Manne, et al.
Haematologica|October 15, 2020
Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletionConstantine S Tam, Tadeusz Robak, Paolo Ghia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2022
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III TrialPeter Hillmen, Barbara Eichhorst, Jennifer R Brown, et al.
Pageof 13